Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

CKD-702

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Chong Kun Dang

Drug class:

c-MET inhibitor, EGFR antagonist

Related drugs:

‹

rezivertinib (2)

cetuximab biosimilar (CDP-1) (0)

KL 140 (cetuximab biosimilar) (0)

savolitinib (29)

amivantamab-vmjw (25)

capmatinib (23)

unecritinib (6)

gumarontinib (5)

JNJ-38877605 (1)

EMD 1204831 (0)

PF-04217903 (0)

rezivertinib (2)

cetuximab biosimilar (CDP-1) (0)

KL 140 (cetuximab biosimilar) (0)

›

MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	CKD-702 Sensitive: C3 – Early Trials CKD-702 Sensitive : C3	CKD-702 Sensitive: C3 – Early Trials CKD-702 Sensitive : C3
MET overexpression	Lung Adenocarcinoma	MET overexpression	Lung Adenocarcinoma	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D
MET exon 14 deletion	Non Small Cell Lung Cancer	MET exon 14 deletion	Non Small Cell Lung Cancer	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D	CKD-702 Sensitive: D – Preclinical CKD-702 Sensitive : D